Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Feb;30(1):51-9.
doi: 10.1007/s10545-006-0384-7. Epub 2006 Dec 11.

The natural history of Niemann-Pick disease type C in the UK

Affiliations

The natural history of Niemann-Pick disease type C in the UK

J Imrie et al. J Inherit Metab Dis. 2007 Feb.

Erratum in

  • J Inherit Metab Dis. 2007 Oct;30(5):833

Abstract

Niemann-Pick disease type C (NPC) is an autosomal recessive, neurovisceral lipid storage disorder. Mutations in two genes (NPC1 and NPC2) produce indistinguishable clinical phenotypes by biochemical mechanisms that have not yet been entirely clarified. The wide spectrum of clinical presentations of NPC includes hepatic and pulmonary disease as well as a range of neuropsychiatric disorders. Late-onset disease has been increasingly recognized as the biochemical diagnosis of NPC has been more widely applied in adult neurology clinics. The clinical presentation and follow-up of 94 patients with NPC is described, 58 of whom were still alive at the time this report was prepared. The age at diagnosis ranged from the prenatal period (with hydrops fetalis) up to 51 years. This review of NPC patients in the UK confirms the phenotypic variability of this inherited lipid storage disorder reported elsewhere. Although a non-neuronopathic variant has been described, most patients in this series who survived childhood inevitably suffered neurological and in some cases neuropsychiatric deterioration. While symptomatic treatment, such as anticholinergic and antiepileptic drugs, can alleviate some aspects of the disease, there is a clear need to develop a specific treatment for this progressively debilitating neurodegenerative disorder.

PubMed Disclaimer

Similar articles

Cited by

References

    1. J Biol Chem. 1992 Nov 25;267(33):23797-805 - PubMed
    1. Biochim Biophys Acta. 1991 Jun 5;1096(4):328-37 - PubMed
    1. J Pediatr. 1993 Aug;123(2):242-7 - PubMed
    1. J Inherit Metab Dis. 2004;27(6):757-66 - PubMed
    1. Biochim Biophys Acta. 2004 Oct 11;1685(1-3):14-21 - PubMed

LinkOut - more resources